| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/08/2001 | CN1069317C Novel indane-2-mercaptoacetamide disulfide derivs, useful as inhibitors of enkephaliinase |
| 08/08/2001 | CN1069309C N-(aminopropyl)-N-phenyl-5,6,7,8-tetrahydronaphtalene-2-carboxamide derivative, preparation and application thereof |
| 08/07/2001 | US6271380 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands |
| 08/07/2001 | US6271261 Chemokine mediated diseases, binding interleukins or beta-receptors and administering to mammals |
| 08/07/2001 | US6271249 Diphenyl imidazoles as potassium channel modulators |
| 08/07/2001 | US6271245 Hydroxamic acid derivatives |
| 08/07/2001 | US6271225 Fused thiophene compounds and medicinal use thereof |
| 08/07/2001 | US6271213 Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue |
| 08/07/2001 | US6271196 Polypeptide |
| 08/07/2001 | US6271015 A polypeptide having an amino acid sequence that hydrolysizes cis-9,10-octadecenoamide and other soporific fatty acid amides; therapy for sleep disorders and narcolepsy |
| 08/07/2001 | US6270992 Histidine kinase of Staphylococcus aureus |
| 08/07/2001 | US6270989 A homologous recombinant dna construct comprising a targeting sequence, an exogenous regulatory sequence, an exon and an unpaired splice donor site at the 3'end; gene therapy for thrombopoietin, thrombocytopenia, multiple sclerosis |
| 08/07/2001 | US6270759 Method of using IL-11 for treating gingivitis |
| 08/07/2001 | CA2213197C Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands |
| 08/07/2001 | CA2191101C Materials and methods for treatment of plaquing diseases |
| 08/07/2001 | CA2015296C Pyranyl cyanoguanidine derivatives |
| 08/02/2001 | WO2001055725A2 Diagnosis of tauopathies determining tau/phospho-tau ratio |
| 08/02/2001 | WO2001055692A2 Neurosteroids as markers for alzheimer's disease |
| 08/02/2001 | WO2001055432A2 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications |
| 08/02/2001 | WO2001055430A1 17 human secreted proteins |
| 08/02/2001 | WO2001055358A2 Phosphodiesterases |
| 08/02/2001 | WO2001055356A2 Human protein kinases and protein kinase-like enzymes |
| 08/02/2001 | WO2001055336A2 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | WO2001055219A2 scsCNTFR/NNT-1 FUSION PROTEIN |
| 08/02/2001 | WO2001055215A1 Therapeutic peptides |
| 08/02/2001 | WO2001055199A1 Peptide fragments of colostrinin and their use |
| 08/02/2001 | WO2001055172A2 ISOLATED COMPLEX COMPRISING A NNT-1 PROTEIN AND IN ADDITION AT LEAST A CLF-1 PROTEIN AND/OR A sCNTFRα PROTEIN |
| 08/02/2001 | WO2001055150A1 4-heteroaryl-1,4-diazabicyclo[3.2.2]nonane, preparation and therapeutic use thereof |
| 08/02/2001 | WO2001055148A1 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| 08/02/2001 | WO2001055134A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors |
| 08/02/2001 | WO2001055133A1 Substituted tryptophan derivatives |
| 08/02/2001 | WO2001055132A1 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists |
| 08/02/2001 | WO2001055130A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 08/02/2001 | WO2001055122A1 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
| 08/02/2001 | WO2001055121A1 Azepine derivatives |
| 08/02/2001 | WO2001055119A2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 08/02/2001 | WO2001055112A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | WO2001055110A1 Isatine derivatives with neurotrophic activity |
| 08/02/2001 | WO2001055106A2 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | WO2001055103A2 Chimeric neuropeptide y receptors |
| 08/02/2001 | WO2001055094A1 Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate |
| 08/02/2001 | WO2001055093A1 N-arylhydrazide compounds and use thereof as drugs |
| 08/02/2001 | WO2001055083A1 Inositol derivatives and their pharmaceutical use |
| 08/02/2001 | WO2001055082A2 Intermediates for biologically active compounds |
| 08/02/2001 | WO2001054771A2 Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 08/02/2001 | WO2001054731A2 Ligand conjugates and methods for preparing same |
| 08/02/2001 | WO2001054721A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases |
| 08/02/2001 | WO2001054699A1 Selective estrogen receptor modulators in combination with estrogens |
| 08/02/2001 | WO2001054697A1 Herbal supplement for cognitive related impairment due to estrogen loss |
| 08/02/2001 | WO2001054694A1 Tetrahydropyrimidone inhibitors of fatty acid binding protein and method |
| 08/02/2001 | WO2001054683A1 Ibuprofen containing active agent preparation |
| 08/02/2001 | WO2001054682A1 Remedies |
| 08/02/2001 | WO2001054681A2 Composition for treatment of stress |
| 08/02/2001 | WO2001054680A2 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 08/02/2001 | WO2001054667A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | WO2001054648A2 Treatment of disorders affecting vigilance related to myopathies |
| 08/02/2001 | WO2001054481A2 Enhanced propertied pharmaceuticals |
| 08/02/2001 | WO2001016114A3 Heterocyclic compounds and methods for modulating cxcr3 function |
| 08/02/2001 | WO2001014548A3 New g-protein coupled receptor and dna sequences thereof |
| 08/02/2001 | WO2001014330A3 Phenylpiperazines as serotonin reuptake inhibitors |
| 08/02/2001 | WO2001012189A8 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 08/02/2001 | WO2001005385A3 New use of a macrolide compound for treating neurodegenerative disorders |
| 08/02/2001 | WO2001004305A3 Human proteins involved in detoxification |
| 08/02/2001 | WO2001004112A3 Benzofurane derivatives |
| 08/02/2001 | WO2000070036A3 Genes expressed in hippocampus |
| 08/02/2001 | WO2000050451A3 Protein (tp) that is involved in the development of the nervous system |
| 08/02/2001 | WO2000047625A3 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 08/02/2001 | WO2000047603A3 16-hydroxyestratrienes as selective estrogens |
| 08/02/2001 | WO1999066918A8 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| 08/02/2001 | US20010011146 Pevention cell degradation |
| 08/02/2001 | US20010011126 Isolated protein; genetic engineering |
| 08/02/2001 | US20010011124 Genetic engineering |
| 08/02/2001 | US20010011103 Pure isomers |
| 08/02/2001 | US20010011093 Arylgycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 08/02/2001 | US20010011091 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists |
| 08/02/2001 | US20010011084 Use of estrogen to modify the amount of serotonin transporter or its mrna |
| 08/02/2001 | US20010011081 Pharmaceutical composition comprising L- carnitine or alkanoyl L-carnitine for the prevention and treatment of diseases brought about by lipid metabolism disorders |
| 08/02/2001 | US20010011077 Secreted cysteine rich protein-6 (SCRP-6); polynucleotides and processes for producing polypeptides |
| 08/02/2001 | US20010011072 Skin disorders; kidney and liver disorders |
| 08/02/2001 | US20010010934 Polypeptides that regulate epithelial specific gene expression; hypoproliferative disorders; medical diagnosis |
| 08/02/2001 | US20010010913 Isolated polypeptide |
| 08/02/2001 | EP1144431A3 16-hydroxyestratrienes as selective estrogens |
| 08/02/2001 | DE10004157A1 New pyridyl- or pyrimidinyl-substituted bicyclic pyrrole derivatives, are cyclokine release inhibitors useful for treating immune system-related disorders, e.g. cancer, multiple sclerosis or arthritis |
| 08/02/2001 | DE10003757A1 Ibuprofen-Wirkstoffzubereitung Ibuprofen drug preparation |
| 08/02/2001 | CA2401086A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases |
| 08/02/2001 | CA2398821A1 Composition for treatment of stress |
| 08/02/2001 | CA2398728A1 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | CA2398561A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
| 08/02/2001 | CA2398546A1 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | CA2398435A1 Novel ligands and methods for preparing same |
| 08/02/2001 | CA2398430A1 Human protein kinases and protein kinase-like enzymes |
| 08/02/2001 | CA2398358A1 The neurosteroid dhea as a marker for neuropathologies |
| 08/02/2001 | CA2398288A1 Ibuprofen containing active agent preparation |
| 08/02/2001 | CA2398283A1 Peptide fragments of colostrinin and their use |
| 08/02/2001 | CA2398227A1 17 human secreted proteins |
| 08/02/2001 | CA2398104A1 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications |
| 08/02/2001 | CA2398003A1 Phosphodiesterases |
| 08/02/2001 | CA2397991A1 Diagnosis of tauopathies determining tau/phospho-tau ratio |
| 08/02/2001 | CA2397831A1 Enhanced propertied pharmaceuticals |
| 08/02/2001 | CA2397758A1 Monohydrate of cis-lithium-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate |